Biocon Biologics Achieves Key Market Access for Yesintek™
Biocon Biologics Ltd. (BBL), a leader in the global biosimilars sector, has made significant strides by establishing market access agreements for its product Yesintek™ (ustekinumab-kfce), a biosimilar to Stelara®. These agreements cover over 100 million lives, illustrating the growing acceptance and trust in Biocon's innovative solutions within the healthcare landscape.
Yesintek's Formulary Additions
The addition of Yesintek™ to prominent health plans is a vital development in expanding patient access to essential treatments. Notable companies like Express Scripts, Cigna, UnitedHealthcare, CVS Health, and Optum Rx have included Yesintek™ in their formularies. This strategic inclusion will begin as early as March and span through multiple months, reflecting the trust in Biocon's biosimilar offerings.
Expert Insights on Yesintek™
Shreehas Tambe, CEO and Managing Director of Biocon Biologics, emphasized the importance of this rollout, stating, "Yesintek™ represents a significant advancement for us, marking our entry as a fully integrated biosimilars company in the United States. The extensive adoption among payors indicates their confidence in the reliability of our science and operations. It's crucial for enhancing access to affordable therapies in the United States market."
Moreover, the Head of North America for Biocon Biologics, Josh Salsi, noted that Yesintek™ is now available to over 100 million Americans. This encompasses a substantial portion of the commercial market, which represents a pivotal move towards increasing the availability of high-quality, cost-effective biosimilars for individuals with chronic health conditions.
Indications and Treatment Scope of Yesintek™
Yesintek™ is designed to treat various chronic conditions, including Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The treatment is available in multiple formulations, ensuring that healthcare providers have options for patient care based on individual needs. The drug works by targeting interleukin-12 and -23 pathways, mechanisms known to play a critical role in inflammatory and autoimmune conditions.
Commitment to Safety and Efficacy
Clinical research has indicated that Yesintek™ mirrors the pharmacokinetic, safety, and efficacy profiles of Stelara®. This robust data supports its role as a credible treatment alternative, providing physicians and patients with greater confidence in utilizing this biosimilar. Yesintek™ not only offers similar therapeutic effects but also aims to make advanced treatments more accessible and affordable, which is crucial for many patients managing chronic conditions.
Comprehensive Future Plans
Biocon Biologics continues to work diligently to expand its reach and finalize formulary agreements with various commercial carriers, thus enhancing patient access further. With Hello, thoughtful development and ongoing commitment to high-quality biosimilars, the company positions itself as an essential player in the landscape of affordable healthcare solutions.
Frequently Asked Questions
What is Yesintek™?
Yesintek™ is a biosimilar to Stelara® (ustekinumab) developed by Biocon Biologics for the treatment of autoimmune diseases.
How does Yesintek™ work?
Yesintek™ disrupts IL-12 and IL-23 mediated signaling, which are pivotal in the inflammation process associated with chronic autoimmune diseases.
Who can benefit from Yesintek™?
The treatment is indicated for adults and pediatric patients with moderate to severe plaque psoriasis, crohn's disease, ulcerative colitis, and psoriatic arthritis.
What are the key achievements of Biocon Biologics?
Biocon Biologics has secured numerous market access agreements for Yesintek™, covering over 100 million lives, impacting many patients and their treatments positively.
What is the goal of Biocon Biologics?
Biocon Biologics aims to transform healthcare by providing affordable access to high-quality biosimilars, enhancing treatment options for patients worldwide.
